Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL)'s chief scientific officer Mark Bleackley speaks with Proactive soon after completing preliminary data analysis from its Phase 2 proof-of-concept clinical trial investigating novel cannabinoid combination drug candidate IHL-42X for the treatment of obstructive sleep apnoea. The clinical trial assessed the efficacy of three doses of IHL-42X – compared to a placebo – in reducing the apnoea hypopnoea index (AHI). The AHI is the main diagnostic and monitoring criteria for OSA in patients who suffer from the disease.
Incannex Healthcare welcomes positive preliminary data from obstructive sleep apnoea trial
